跳至主要内容

Medicilon was selected into the "2023 Shanghai Hardcore Technology Enterprises TOP 100 List"

 2023 Shanghai Hardcore Technology Enterprises TOP 100 List.webp

On March 25, the Shanghai Industrial Technology Innovation Promotion Association, the City Association for Science and Technology and the Baoshan District Government released the "2023 Shanghai Hardcore Technology Enterprises TOP100 List".  The selected companies from the list covers enterprise technology centers, listed companies, top 100 emerging industries, top 100 private manufacturing companies, and companies undertaking major municipal-level scientific and technological projects.

Shanghai Medicilon Inc. stood out from more than 1,500 outstanding companies and was successfully selected into the list of "2023 Shanghai Hardcore Technology Enterprises TOP 100 List".

The recognition of Shanghai's hard-core technology enterprise is the official recognition of Medicilon's comprehensive R&D technology innovation, technical service platform, and drug R&D empowerment.  It is also an affirmation of Medicilon's achievements in the field of pharmaceutical research and development, as well as its influence and driving force on the industry.

评论

此博客中的热门博文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites   On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

In Vitro Enzyme Activity Assay

  Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+  in vitro  enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

Pharmacokinetics Services

Pharmacokinetics Services Our pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government. Preclinical Pharmacokinetics Method development and validation (GLP,Non-GLP) Bioanalysis Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration ) Stability in vehicles and plasma Drug interaction studies In vitro metabolic stability CYP 450 inhibition Plasma protein binding studies Distribution studies Excretion studies Prediction an...